Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium pseudolongum
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium pseudolongum is a beneficial gut bacterium that plays a significant role in modulating gut microbiota composition and influencing various physiological processes. It has been shown to alleviate intestinal injury, reduce inflammation, and contribute to anti-tumor immunity through its exopolysaccharides (EPSs) which are sensed by dendritic cells via TLR2-MyD88, leading to the induction of IL-12 and TNF-α. It also produces beneficial metabolites such as propionic acid (PA) and indoleacetic acid (IAA), which are linked to cognitive function and neuroprotection. Furthermore, B. pseudolongum is involved in cholesterol-lowering mechanisms by modulating the FXR-FGF15-CYP7A1 axis and contributes to intestinal radioprotection by increasing creatine levels and activating AMP-activated protein kinase (AMPK). Its dysregulation or supplementation has been implicated in conditions such as ketamine-induced cystitis, hyperglycemia-induced osteoporosis, morphine tolerance, fatty liver disease, Henoch-Schönlein purpura, depression, and Alzheimer's disease.
- Other names
- B. pseudolongum
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on bifidobacterium pseudolongum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium pseudolongum.